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The synthetic glycoside, oleyl N-acetyl-R-D-glucosaminide (1), was previously shown to exhibit antimitotic
activity on rat (C6) and human (U-373) glioma lines. To obtain information about its mechanism of action,
metabolite changes in C6 glioma cells were analyzed after treatment with 1 using high-resolution magic
angle spinning 1H NMR. Compound 1 caused either a decrease or an increase in the intensity of the signal
assigned to coenzyme A (CoA) metabolites depending on the concentration used. The data obtained from
the 1H NMR spectra of cells cultured with 1, combined with those obtained after treatment with oleic acid
(an inhibitor of acetyl-CoA carboxylase) and phenyl butyrate (a known antineoplastic agent), suggest that
1 may be altering the metabolism of fatty acids and induce apoptosis of C6 glioma cells. These results point
to NMR spectroscopy as an efficient technique for monitoring the response of the cells to therapeutic agents.
Introduction
The treatment of glioma has yielded only meager increases
in survival time in spite of important advances in therapeutic
oncology. Only half of the patients receiving standard treatment
for brain tumor in the U.S. survived one year after diagnosis.1
The investigation of synthetic compounds able to slow down
glioma progression is, therefore, of great interest.
The presence in brain extracts of inhibitors of astroblast and
astrocytoma division was first described by one of us.2 On the
basis of structural elements of the natural inhibitor, we
synthesized series of oligo- and monosaccharides, which were
tested as inhibitors of brain tumor cell division.3-7 Recently
we have obtained a family of N-acyl-glucosamine derivatives,
some of which showed antimitotic activity against rat C6 glioma
cells with low IC50 values.7 The results obtained indicated that
the activity was increased by a long hydrocarbon chain at
position C-1 of the glucosamine backbone, the most inhibitory
compound being the oleyl glycoside 1 (Chart 1).
Because of the high antiproliferative activity exhibited by 1,
it was of interest to obtain information about its mode of action,
which could be of great value in designing new compounds
with improved therapeutic properties. With this purpose, we
have analyzed changes in low molecular weight metabolites after
treatment of C6 glioma cells with 1 using high-resolution magic
angle spinning (HR-MAS) 1H NMR.
The NMR approach used to study liquids (i.e., body fluids
and tissue extracts) leads to poorly resolved proton spectra when
it is applied to investigate intact cells and tissues. The main
two factors contributing to the observed peak broadening are
the chemical and physical heterogeneity present in these
samples. Thus, they have a wide variety of metabolites with
functional groups having their chemical shifts overlapping in a
relatively narrow region of the proton spectrum. The hetero-
geneous nature of the samples also results in regional differences
in magnetic susceptibility that give rise to local field gradients
and, consequently, to a dispersion of the spectral frequencies
associated to each chemical moiety. Additional causes of line
broadening are the residual dipolar spin interactions and
chemical shift anisotropy. The restricted or anisotropic molecular
motion in solid-like samples, such as those of interest in this
work, hampers the reduction of these contributions to the
resonance linewidths, as it occurs in liquids where the rapid
isotropic molecular motion averages them to zero. One approach
to reduce or minimize the contribution of the interactions
indicated above to the peak broadening involves spinning the
sample sufficiently fast at an angle θ ) 54° 44′ relative to the
spectrometer static magnetic field B0 (i.e., the “magic-angle”
where contributions proportional to: 3cos2 θ - 1 ) 0).8-10 In
this regard, proton MAS NMR combined with T2-filtering has
been used to narrow the resonances from small molecules and
improve the resolution of intact cells and tissues spectra,
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allowing weak resonances associated with metabolites present
at low concentrations to be revealed.11-15 The nondestructive
nature of the technique allows the acquisition of metabolic
information directly from cells with minimal preparation and
their analysis by other methods. In addition, the solid state
approach offers the advantage over conventional liquid state
NMR (i.e., used in analysis of cells extracts) of simultaneous
observation of lipophilic and hydrophilic metabolites.
One of the pathologies that have been widely studied by NMR
is brain cancer. The spectral pattern of glioblastomas and
cultured glioma cell lines have been studied using NMR
spectroscopy16-18 in an attempt to detect or predict its progres-
sion. Here, we show that the analysis of the 1H NMR spectra
of C6 cells cultured in the presence of 1 has provided clues to
its mechanism of action. Because the main contribution to line
broadening in our case is due to magnetic susceptibility
differences between intracellular structures, slow spinning rates
are sufficient to greatly improve spectral resolution.10,19 Thus,
proton HR-MAS NMR spectra were acquired at moderate
spinning rates, enough to avoid the interference of spinning side
bands in the spectral region of interest while minimizing sample
heating and disruption of cell membranes.11,19 Furthermore, a
T2-filter was used to reduce the interference of macromolecular
protons, including contribution from broad lipid resonances,
enabling nonlipid metabolites to be readily identified. Our results
show that proton HR-MAS NMR spectroscopy is an effective
tool for monitoring the response of the cells to therapeutic
agents.
Results and Discussion
In our previous report,7 we obtained compound 1 in a single
reaction step by Fisher type glycosylation of oleic alcohol with
N-acetyl-D-glucosamine in the presence of BF3 ·OEt2, although
in a low yield (10%). After evaluating several conditions and
acid promoters, we improved the synthetic procedure by using
H2SO4 adsorbed on silica20 as catalyst, which afforded 1 in 38%
yield. This procedure presents the advantage of using a solid
catalyst, which is easier and safer to handle than BF3 ·OEt2.
Proton T2-filtered MAS NMR spectroscopy was used to study
the effect of 1 on C6 metabolic profile. The T2-filter consisted
of a CPMG pulse sequence with 90° rf pulse followed by a
train of thirty 180° rf pulses spaced 2 ms apart. The effective
echo time was 60 ms. In addition, to suppress the water protons
signal, low power continuous irradiation rf during the waiting
period was applied.
The 1H NMR spectra of C6 glioma cells after 24 h of
incubation is shown in Figure 1a. The assignment of relevant
signals was based on the chemical shifts reported for metabolites
of cultured glioma cell lines.18,21 Thus, the peak centered at
3.23 ppm was assigned to the total choline trimethyl resonance
(tCho) and consists of at least three different choline subspecies
(choline, glycerophophocholine, and phosphocholine). A broad
peak at 1.3 ppm is due to the resonances from lipid methylene
groups and from lactate methyl group. The resonance at the
lowest chemical shift, 0.67 ppm, corresponds to one of the
methyl groups of the isopropyliden moiety of coenzyme A
(CoA) metabolites, although contribution of the methyl group
of cholesterol cannot be excluded. The assignment of this signal
is facilitated by its occurrence in a relatively uncrowded region
and well-separated from the peak at 0.9 ppm containing the
resonances from methyl groups of lipids and proteins. The
presence of a relatively intense peak of CoA metabolites can
be associated to the fact that tumors in general, and this cell
line in particular,18 undergo exacerbated de novo biogenesis of
fatty acids, a process that is necessary to maintain a constant
supply of lipids and lipid precursors to fuel membrane produc-
tion. During lipogenesis, tumor cells present high steady state
levels of malonyl-CoA (Scheme 1). Therefore, this metabolite
must be the main compound contributing to the signal at 0.67
ppm.
The most significant metabolic change detected by 1H NMR
spectroscopy after treatment with 1 (10 µM) for 24 h was the
decrease in the signal at 0.67 ppm from CoA metabolites (Figure
1b). This reduction was quantified using the resonance from
creatines, which is centered at 3.00 ppm. Creatine is a commonly
used internal concentration reference for in vivo 1H NMR21
because its concentration correlates with the number of meta-
bolically active cells and is used as a measure of viable cell
count. Thus, the ratio CoA/creatine in the controls was 0.78 (
0.07, while in treated cells was 0.32 ( 0.07. Considering the
biosynthetic route in Scheme 1, the reduction of the intensity
of this peak suggests that 1 could be inhibiting the synthesis of
fatty acid at the step of malonyl-CoA formation, namely the
carboxylation of acetyl-CoA. A recent report showed that oleic
acid strongly reduced acetyl-CoA carboxylase activity and was
an inhibitor of fatty acid synthesis in C6 glioma cells.22
Interestingly, compound 1 is a glycoside of oleyl alcohol, and
the presence of the oleyl group was the main structural
difference with respect to the parent glycosides that resulted
less inhibitory of glioma cell division than 1.7 The treatment of
Figure 1. NMR spectra 24 h, T2 ) 60 ms, ns ) 500. (a) C6 control.
(b) C6 + 1 (10 µM). (c) C6 + oleic acid (100 µM). tCho, total choline
trimethyl resonance; tCoA, total coenzyme A methyl resonance.
Scheme 1. Schematic Representation of Fatty Acid
Biosynthesisa
a ACC, acetyl-CoA carboxylase; FAS, fatty acid synthase.
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C6 cells with oleic acid (100 µM) for 24 h afforded a 1H NMR
spectrum similar to that obtained with 1 (10 µM) (Figure 1c),
in which the major metabolic change was also the intensity of
the signal at 0.67 ppm. In this case, a 3-fold decrease in the
peak intensity from CoA metabolites was observed. The parallel
behavior of 1 and oleic acid seems to indicate that the glycoside
could also be inhibiting acetyl-CoA carboxylase activity.
Longer incubation (48 h) with 1 gave a spectrum in which
no signal for CoA metabolites was observed and the concentra-
tion of choline-containing metabolites was increased as com-
pared to control (Figure 2). The choline signal in 1-treated cells
increased more than 3-fold, considering the peak of creatine as
reference (2.47 ( 1.14 versus 0.72 ( 0.37 for treated and control
cells, respectively). It has been reported that in the early phase
of programmed cell death in rat brain glioma, the concentration
of choline metabolites increases, as determined by 1H NMR
spectroscopy.23 This increase may reflect altered metabolism
as a result of choline kinase activation accompanied by
simultaneous membrane breakdown through phospholipases. In
addition, a slight increase of the signal intensity at 1.3 ppm,
assigned to the methylene protons of mobile lipids, was
observed. An association between lipid body formation and cell
death has been demonstrated in a number of drug-treated cell
models.24 Therefore, the 1H NMR spectrum after treatment with
10 µM of 1 for 48 h suggests that a certain number of glioma
cells entered apoptosis.
The typical characteristics of apoptotic cell death were verified
by the analysis of DNA fragmentation induced by 1. Figure 3
shows that the incubation of C6 cells with 80 µM of 1 resulted
in DNA laddering after 19 h of incubation, demonstrating that
cell death was indeed an apoptotic and not a necrotic process.
A high ratio of DNA fragmentation was already observed with
40 µM of 1, while no appreciable DNA fragmentation was
observed at 10 µM after 19 h. The latter suggests that the
previously discussed changes in the 1H NMR spectrum of cells
after 48 h incubation with 10 µM correspond to the apoptotic
signals for a small population of cells.
In view of these results, the 1H NMR spectra of cells cultured
at higher concentrations of 1 were registered. The spectrum of
cells treated with 40 µM of 1 shows a decline of the intensity
of all the signals (Figure 4b), indicating a decrease in cell
population density due to the inhibitory effect of 1, with a high
ratio of cell death as shown by the small intensity of the peak
from creatine. Experiments performed at even higher concentra-
tions (i.e., 100 µM; data not shown) lead to very small number
of viable cells hampering any quantitative analysis. These results
were anticipated in view of findings from DNA fragmentation
experiments. In addition, the signal for CoA metabolites at 0.67
ppm was significantly high, in contrast to the effect observed
when the incubation was performed with 10 µM of 1, namely
the disappearance of this signal. It has been postulated that under
stress conditions glioma cells used the fatty acid oxidation as
protective mechanism.25 Under this hypothesis, we reasoned that
at 40 µM concentration of 1, when cell death occurs, the
oxidation of fatty acids is taking place. During the oxidative
process high levels of acetyl-CoA are formed. In this sense,
the presence of a sharp peak at 2.24 ppm ascribed to the acetyl
group of acetyl-CoA confirmed the assignment of this metabo-
lite. To check whether the resonances from this metabolite are
indicative of a cell death process, cells were treated with
phenylbutyrate (PB), a chemotherapeutic agent that has been
Figure 2. NMR spectra 48 h, T2 ) 60 ms, ns ) 1000. (a) C6 control.
(b) C6 + 1 (10 µM).
Figure 3. DNA fragmentation of C6 cells treated with 1 at different
concentrations (µM).
Figure 4. NMR spectra 24 h, T2 ) 60 ms, ns ) 500. (a) C6 control.
(b) C6 + 1 (40 µM). (c) C6 + PB (10 mM).
Detection of Metabolite Changes in C6 Glioma Cells Journal of Medicinal Chemistry, 2009, Vol. 52, No. 5 1265
shown to induce apoptosis in certain malignant cells.26,27 The
1H NMR spectrum after incubation with PB (10 mM) for 24 h
showed also a profile for low cell density and viability and,
additionally, a significant accumulation of mobile lipids (Figure
4c). In agreement with our expectation, a high increased of the
signals assigned to acetyl-CoA was also observed (peaks at 2.24
and 0.67 ppm).
The data obtained from the 1H NMR spectra of the different
experiments suggest that 1 may inhibit cell division at concen-
trations around 10 µM (the IC50 value for 1 was 1.4 µM)7 by
inhibiting de novo synthesis of fatty acids. At higher concentra-
tions (above 40 µM), a significant ratio of cell death occurred
through an apoptotic process. The mechanism by which apo-
ptosis takes place would be the objective of our future
investigations. In this context, it is worth mentioning that 1
shares structural elements with ceramide analogues S18 and
T18, which have been shown to induce apoptosis (Figure 5).28
The proapoptotic activity required the presence of at least two
hydroxy alkyl branches and an amido-linkage to the fatty (oleic)
acid chain. The authors suggested that these compounds could
be acting directly at the apoptotic targets for ceramide.
In conclusion, the present work shows for the first time to
our knowledge that intensity of the signals associated to CoA
metabolites in the HR-MAS 1H NMR spectrum of intact glioma
cells are significantly affected by an antitumoral agent that
induces apoptosis. The decrease or increase in intensity of peaks
assigned to CoA metabolites seems to be related to either the
inhibition of lipid synthesis or the activation of lipid oxidation,
respectively. The current interest29,30 concerning the role of lipid
synthesis in cancer progression makes this observation of special
relevance.
Our results, supported by others using structurally related
molecules, point out that the conjugation of an oleyl moiety
with a sugar can result in compounds able to inhibit cell division
and induce cell death in glioma cell lines, raising expectations
to generate promising candidates to treat one of the most deadly
forms of cancer.
Experimental Section
Chemistry. General Methods. Thin-layer chromatography
(TLC) was performed on aluminum sheets 60 F254 Merck silica
gel, and compounds were visualized by irradiation with UV light
and/or by treatment with a solution of Ce2MoO4 or 5% H2SO4 in
EtOH, followed by heating. Flash column chromatography was
performed using thick walled column, employing silica gel (Merck
60: 0.040-0.063 mm). The eluent used is indicated, and solvent
ratios refer to volume. Optical rotation was recorded on a Perkin-
Elmer 241 polarimeter (λ ) 589 nm, 1dm cell). The purity of
compound 1 was g95% as determined by combustion analysis,
recorded on a Heraus CHN-O Rapid analyzer.
Oleyl 2-acetamido-2-deoxy-r-D-glucopyranoside (1). For the
preparation of the acid catalyst,20 10 g of silica gel (200-325 mesh)
were suspended in diethyl ether (50 mL) and concentrated H2SO4
(3 mL) was slowly added dropwise under agitation. During the
adsorption process, over 10 min, the suspension was gently shaken
at room temperature. Then the solvent was removed by flash
distillation at 60 °C under reduced pressure and the silica was dried
at 60 °C under reduced pressure (2-4 mbar) for 3 h. Afterward,
N-acetyl glucosamine (500 mg, 2.26 mmol) and 85% oleic alcohol
(4.1 mL, 11.3 mmol) were dissolved in nitromethane (2 mL) under
argon and H2SO4 adsorbed on silica (50 mg) was added. The
reaction mixture was stirred at 100 °C for 4 h. After this time
elapsed, the reaction mixture was cooled down to room temperature,
the solvent was removed by flash distillation, and the residue was
purifiedbysilicagelcolumnchromatography(ethylacetate-methanol,
10:0 f 10:1) to give 1 (404 mg, 38%). [R]D: +103.1° (c 0.95,
MeOH). 1H and 13C NMR spectrum was identical to that previously
described.7
Cell Culture. Rat C6 glioma cells were from the American Type
Culture Collection. DMEM cell culture medium, penicillin (100
U/mL), and streptomycin (100 µg/mL) were all purchased from
Sigma-Aldrich (Steinheim, Germany) and supplemented with 10%
Linus fetal calf serum (FCS) from Cultek (Madrid, Spain). The
cell cultures were maintained in a humidified atmosphere of 5%
CO2 at 37 °C.
The C6 cells were seeded on plastic flasks at a density of 2 ×
105 cells/cm2 and allowed to attach for 6 h. After the cells were
attached to the substrate, the medium was changed to DMEM
without serum and the cells were incubated for 24 h. Then medium
was replaced by DMEM plus 1% FCS containing the test
compounds. The cell cultures were incubated for 24 or 48 h,
harvested, centrifuged, and suspended in cold phosphate buffer
solution (PBS) for further analysis. Each experiment was made by
triplicate, and cells without any compound were used as control.
DNA Fragmentation Assay. To examine the fragmentation of
DNA, the treated and control C6 cells were centrifuged at 800g
for 10 min. Cell pellets were homogenized in 1 mL of TRIzol
Reagent (Invitrogen, Madrid, Spain), and DNA isolation protocol
recommended by suppliers was followed. Briefly, chloroform was
added to homogenized samples and centrifuged by 15 min at 10000g
in a microcentrifuge (Eppendorf, Hamburg, Germany). The DNA
was isolated from interphase and organic phase and precipitated
with 100% ethanol. The DNA pellet was washed two times with
solution containing 0.1 M sodium citrate in 10% ethanol, suspended
in 75% ethanol, and centrifuged at 2000g. The resulting DNA pellet
was dissolved in 8 mM NaOH and adjusted to pH ) 8.0 with TE
solution. DNA samples were incubated with RNase A (final 1 mg/
mL) by 1 h at 37 °C and then with proteinase K (final 1 mg/mL)
at 37 °C for another 1 h. The samples were analyzed by
electrophoresis in 1.5% agarose gel, stained previously with SYBR
Safe DNA gel stain (Invitrogen, Molecular Probes, Oregon) and
finally visualized under UV light.
NMR Spectroscopy. High-resolution proton MAS NMR mea-
surements were performed on a Bruker Avance 400 wide bore (89
mm Ø) spectrometer (Bruker Instruments, Karlsruhe, Germany)
operating at 9.4 T (proton Larmor frecuency at 400.14 MHz). All
spectra were acquired at 20 °C (293 K) using a Bruker double-
tuned broadband solid state CP/MAS probe head. After incubating
the cells in the medium with the corresponding compound, they
were washed with deuterated phosphate buffered solution and
centrifuged to form pellets. Typically, for each sample ap-
proximately 60 µL of cell pellets were placed into a 4 mm Ø
zirconia rotor. The spectra were acquired using a 90° pulse of 3.35
Figure 5. Structure of ceramide analogues S18 and T18 known to
induce apoptosis (ref 28).
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µs followed by a T2 filter of 60 ms. On selected samples (data not
shown), spectra were acquired varying the T2 filter between 30 and
600 ms. The filter of 60 ms was chosen as the best compromise
between total acquisition time, signal-to-noise ratio, and spectral
resolution. The spinning rate was 2.4 kHz. The spectral width was
8.3 kHz, 16 k data points, and the number of scans varied between
500 and 1000 with a repetition rate of 5 s. The residual water signal
was suppressed by presaturation on the water resonance. All FIDs
were processed with a 2 Hz line broadening and the chemical shifts
referenced to internal DSS (5 µL of a 10 mM solution) (0.00 ppm).
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